References
- International Diabetes Federation. IDF diabetes atlas. 7th ed. 2015 [cited 2015 Dec 9]. Available from: http://www.diabetesatlas.org.
- Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314:1021–1029.
- American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl):S8–S16.
- Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
- Blomberg B, Spinaci S, Fourie B, et al. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ. 2001;79:61–68.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2015 [cited 2015 Aug 24]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
- Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213–224.
- Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30:2415–2422.
- DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811.
- Sabaté E. Adherence to long-term therapies: evidence for action. Geneva (Switzerland): World Health Organization; 2003. Available from: http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf.
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
- Abughosh SM, Wang X, Serna O, et al. A pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a medicare advantage plan. J Manag Care Spec Pharm. 2016;22:63–73.
- Viswanathan M, Golin CE, Jones CD, et al. Medication adherence interventions: comparative effectiveness closing the quality gap: revisiting the state of the science. Evidence Report No. 208. (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I.) AHRQ Publication No. 12-E010-EF. Rockville (MD): Agency for Healthcare Research and Quality. 2012 Sep [cited 2016 Jul 28]. Available from: https://effectivehealthcare.ahrq.gov/ehc/products/296/1248/EvidenceReport208_CQGMedAdherence_FinalReport_20120905.pdf.
- Lokhandwala T, Smith N, Sternhufvud C, et al. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19:203–212.
- Fontil V, Pletcher MJ, Khanna R, et al. Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010. J Gen Intern Med. 2014;29:468–476.
- Hampp C, Borders-Hemphill V, Moeny DG, et al. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37:1367–1374.
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140–149.
- Harper W, Clement M, Goldenberg R, et al. Pharmacologic management of type 2 diabetes. Can J Diabetes. 2013;37(Suppl 1):S61–S68.
- Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417.
- Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859–1864.
- Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) group. JAMA. 1999;281:2005–2012.
- Blüher M, Kurz I, Dannenmaier S, et al. Pill burden in patients with type 2 diabetes in Germany: subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes. 2015;33:55–61.
- Triplitt C. Improving treatment success rates for type 2 diabetes: recommendations for a changing environment. Am J Manag Care. 2010;16:S195–S200.
- Timmins P, Donahue S, Meeker J, et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44:721–729.
- Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29:759–764.
- Boehringer Ingelheim. Jentadueto XR (linagliptin and metformin hydrochloride extended-release) prescribing information. 2016 [cited 2016 Jul 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208026s000lbl.pdf.
- AstraZeneca Pharmaceuticals. Kombiglyze XR (saxagliptin and metformin hydrochloride extended-release) prescribing information. 2015 [cited 2016 Feb 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf.
- Merck & Co. Janumet XR (sitagliptin and metformin hydrochloride extended-release) prescribing information. 2015 [cited 2016 Feb 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202270s010lbl.pdf.
- AstraZeneca Pharmaceuticals. Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) prescribing information. 2014 [cited 2016 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205649s003lbl.pdf.
- Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011;123:15–23.
- Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20:565–572.
- Takeda Pharmaceuticals. Kazano (alogliptin and metformin hydrochloride) prescribing information. 2015 [cited 2015 Nov 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203414s005lbl.pdf.
- Boehringer Ingelheim. Jentadueto (linagliptin and metformin hydrochloride) prescribing information. 2015 [cited 2015 Nov 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201281s010lbl.pdf.
- Janssen Pharmaceuticals. Invokamet (canagliflozin and metformin hydrochloride) prescribing information. 2015 [cited 2016 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204353s012lbl.pdf.
- Boehringer Ingelheim. Synjardy (empagliflozin and metformin hydrochloride) prescribing information. 2015 [cited 2016 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206111s002lbl.pdf.
- Takeda Pharmaceuticals. Oseni (alogliptin and pioglitazone) prescribing information. 2015 [cited 2015 Nov 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022426s005lbl.pdf.
- Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292:E871–E883.
- Boehringer Ingelheim. Glyxambi (empagliflozin and linagliptin) prescribing information. 2015 [cited 2016 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206073s003lbl.pdf.
- Bristol-Myers Squibb. Glucophage (metformin) prescribing information. 2009 [cited 2015 Dec 8]. Available from: http://packageinserts.bms.com/pi/pi_glucophage.pdf.
- Boehringer Ingelheim. Tradjenta (linagliptin) prescribing information. 2015 [cited 2015 Dec 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201280s012lbl.pdf.
- Takeda Pharmaceuticals. Nesina (alogliptin) prescribing information. 2015 [cited 2015 Dec 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022271s007lbl.pdf.
- Merck & Co. Januvia (sitagliptin) prescribing information. 2015 [cited 2015 Dec 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021995s034lbl.pdf.
- AstraZeneca Pharmaceuticals. Onglyza (saxagliptin) prescribing information. 2015 [cited 2015 Dec 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022350s016lbl.pdf.
- Janssen Pharmaceuticals. Invokana (canagliflozin) prescribing information. 2015 [cited 2016 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204042s013lbl.pdf.
- AstraZeneca Pharmaceuticals. Farxiga (dapagliflozin) prescribing information. 2015 [cited 2016 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202293s008lbl.pdf.
- Boehringer Ingelheim. Jardiance (empagliflozin) prescribing information. 2015 [cited 2016 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204629s007lbl.pdf.
- Takeda Pharmaceuticals. Actos (pioglitazone hydrochloride) prescribing information. 2013 [cited 2015 Dec 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf.
- Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38:89–101.
- Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:644–652.
- Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14:565–574.
- Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611–622.
- Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–531.
- Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–579.
- Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2014;15:2565–2585.
- Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446–456.
- Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950.
- Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–2592.
- Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650–1659.
- DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5–14.
- Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
- Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700.
- Food and Drug Administration. AstraZeneca receives complete response letter from US FDA for saxagliptin /dapagliflozin fixed-dose-combination. 2015 [cited 2016 Jul 21]. Available from: https://www.astrazeneca.com/our-company/media-centre/press-releases/2015/astrazeneca-receives-complete-response-letter-from-us-16102015.html.
- Food and Drug Administration. AstraZeneca receives approval in the EU for Qtern (saxagliptin and dapagliflozin) for treatment of type 2 diabetes. 2016 [cited 2016 Jul 21]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-receives-approval-in-the-EU-for-Qtern-saxagliptin-and-dapagliflozin-for-treatment-of-Type-2-diabetes.html.
- Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394–402.
- DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
- Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
- Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.
- Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33:2406–2408.
- Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29:1–13.
- Blonde L, San Juan ZT, Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract. 2014;20:1322–1332.
- Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–2097.
- Garber AJ, Donovan DS Jr., Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3598–3604.
- Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825–834.
- Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600–606.
- Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30:807–812.
- Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23:588–594.
- Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–284.
- Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512–1517.
- Benford M, Milligan G, Pike J, et al. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012;29:26–40.
- Blonde L, Wogen J, Kreilick C, et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5:424–431.
- Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–1168.
- Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23:611–614.
- Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893–1907.
- Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460–467.
- Thayer S, Arondekar B, Harley C, et al. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44:791–799.
- Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124–1131.
- Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407.
- Bramlage P, Ketelhut R, Fronk E-M, et al. Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. Clin Drug Investig. 2014;34:403–411.
- Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.
- Nachega JB, Parienti -J-J, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297–1307.
- Ramjan R, Calmy A, Vitoria M, et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health. 2014;19:501–513.
- Hagendorff A, Freytag S, Müller A, et al. Pill burden in hypertensive patients treated with single-pill combination therapy–an observational study. Adv Ther. 2013;30:406–419.
- Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–1152.
- Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS investigators. European stroke prevention study. Thromb Res. 1998;92:S1–S6.
- Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.
- Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918–929.
- Williams B, Shaw A, Durrant R, et al. Patient perspectives on multiple medications versus combined pills: a qualitative study. QJM. 2005;98:885–893.
- Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291–300.